{"name":"Chugai Pharmaceutical","slug":"chugai","ticker":"4519.T","exchange":"TSE","domain":"chugai-pharm.co.jp","description":"Chugai Pharmaceutical Co., Ltd.  is a drug manufacturer operating in Japan. It is a subsidiary controlled by Hoffmann-La Roche, which owns 62% of the company as of 30 June 2014. The company is headquartered in Tokyo. Osamu Nagayama is the current representative director and chairman. Tatsuro Kosaka is the current representative director, president and CEO.","hq":"Tokyo, Japan","founded":1953,"employees":"5104","ceo":"Osamu Okuda","sector":"Oncology / Rare Disease / Antibody Engineering","stockPrice":8096,"stockChange":291,"stockChangePercent":3.73,"marketCap":"$84.2B","metrics":{"revenue":8163758032.874766,"revenueGrowth":11.5,"grossMargin":71.4,"rdSpend":0,"netIncome":2858996327.369533,"cash":5374701205.41474,"dividendYield":1.69,"peRatio":30.7,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Roactemra patent cliff ($1.4B at risk)","drug":"Roactemra","type":"patent_expiry","sentiment":"negative"},{"date":"2034-06-01","label":"Enspryng patent cliff ($0.5B at risk)","drug":"Enspryng","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"ELDECALCITOL","genericName":"ELDECALCITOL","slug":"eldecalcitol","indication":"Osteoporosis","status":"marketed"},{"name":"Tocilicumab","genericName":"Tocilicumab","slug":"tocilicumab","indication":"Other","status":"phase_1"},{"name":"rivavirin","genericName":"rivavirin","slug":"rivavirin","indication":"Other","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ocrelizumabu 200mg","genericName":"ocrelizumabu 200mg","slug":"ocrelizumabu-200mg","indication":"Rheumatoid Arthritis","status":"discontinued"}]}],"pipeline":[{"name":"ELDECALCITOL","genericName":"ELDECALCITOL","slug":"eldecalcitol","phase":"marketed","mechanism":"Vitamin D3 receptor","indications":["Osteoporosis"],"catalyst":""},{"name":"Tocilicumab","genericName":"Tocilicumab","slug":"tocilicumab","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ocrelizumabu 200mg","genericName":"ocrelizumabu 200mg","slug":"ocrelizumabu-200mg","phase":"discontinued","mechanism":"Ocrelizumab selectively depletes CD20+ B lymphocytes to suppress autoimmune-mediated inflammation.","indications":["Rheumatoid Arthritis"],"catalyst":""},{"name":"rivavirin","genericName":"rivavirin","slug":"rivavirin","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-14","type":"regulatory","headline":"Chugai's Enspryng (satralizumab) receives approval in Japan for the treatment of neuromyelitis optica spectrum disorder (NMOSD)","summary":"Chugai announced that Enspryng has been approved in Japan for the treatment of NMOSD, a rare autoimmune disease.","drugName":"Enspryng","sentiment":"positive"},{"date":"2023-08-04","type":"deal","headline":"Chugai and AbbVie announce collaboration to develop and commercialize Chugai's anti-CD73 antibody","summary":"Chugai and AbbVie announced a collaboration to develop and commercialize Chugai's anti-CD73 antibody for the treatment of various cancers.","drugName":"anti-CD73 antibody","sentiment":"positive"},{"date":"2023-05-11","type":"earnings","headline":"Chugai Pharmaceutical reports FY2022 financial results","summary":"Chugai announced its FY2022 financial results, with revenue increasing 12.1% year-over-year.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE8xTE9Lbkxac2ZoeDJHdXZ6RnVjWFF6ckdxSFdaZ0NsRi1RUk1GRzhnMUtxRUJLdURyVUJjZ3ItaFJDMTFxRlQ1UlpRbUpFVG1SUE85eTNkVXRuM3hKUmRaVkFPSVRtUnppZVZuR0l0aVhpWWJYbVRQaGt3?oc=5","date":"2026-02-06","type":"pipeline","source":"The Japan News","summary":"Japanese Drugmakers Slump after Trump Unveils Discount Drug Website - The Japan News","headline":"Japanese Drugmakers Slump after Trump Unveils Discount Drug Website","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxOUDNvUkJmOGVwSnN1Y216V1UxUi1YRTRNN21PcmJrSEFfamJTOXVQd2FOczhLbDlOR3NyLXVqTUo5Q2pRTVMza0VTRnRtd1VqMUdzT0JhUmZZUlNsQUhmU1RNLVpNVUFwRG9uX3Z1cWtQTkVld0Mxc2ZBWHhRX0NPVDRQaG1UOElKT1ZKaUstWEd2YXB1ZDhkWTVqNUNYWS1aQi1xR280emVwaEh6MmJ5c01mejlBc3Ytc3VmQ3N4VkxVZ3I1V2V6M05FMDBTcGhIU2JhdVFB?oc=5","date":"2026-02-05","type":"pipeline","source":"Reuters","summary":"Japanese drugmakers slump after Trump unveils discount drug website - Reuters","headline":"Japanese drugmakers slump after Trump unveils discount drug website","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQZUc1VTZnSXYwT0hoN0ZIWm9NS3N6b1VETnRyMnB1VzRWQXQtZjdhZ29CNE5WSTRJbkhVZHVEbTZuYVZBTktqbnk5WjlqaE1rcDgyTE5CWXZKX3l5MnVxSjZBUURQUjhjcTk2ZC1Ydk96aUdaNDBfOFhVQ25LWUpWYVRFeXVFTFBVbVZfOGtTLU1PMHFnUnhBZU5Oa28zS3kwcDZmU1NNU0RDMEU?oc=5","date":"2025-11-24","type":"pipeline","source":"Quiver Quantitative","summary":"Portfolio Building Block World Pharma and Biotech Index ETF Holdings - Quiver Quantitative","headline":"Portfolio Building Block World Pharma and Biotech Index ETF Holdings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxPZXJnVnZpRDZYOVExZExISWFBNUh1UFhOb3ZickdWVkl2Mk1STC1FcERrcmxXdlRZekROaEdLb1Jybzh3Sl9vRUNXdzJzaVRYZzVOZHhJVi1YU21VUkdwVXU3dk9kaEtkUmt0TU1GTV9EalZFUDdyOUhhZWdnNEdCMDdncVFndXdRNHVlYkQ3QURTM1MzRUNacHVueW9HTGNIVnBkSTlUSk5QT3FzV3o0OHp0RmJldkVHSFhHSHRGdm15Q2E2VnNseG9kYU54LTd6SkYxbk51WDIzbXo1LVFKYXBRcEZ1UQ?oc=5","date":"2025-10-17","type":"deal","source":"Reuters","summary":"Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma - Reuters","headline":"Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPWnYxNmttRk94QlpTZzMzM0tKdVY0QS1IZHc3Y2EwcEpXdjBoaEszaEMyN2tiUlhVMnVHVVZydGlyYy1ram51QU1tR1Y5M2NyRjZ5aUxVOC1CUTI0aGpWSmtWNnVYMG1mYlY0R3JkekNBSHJoUGtuX0FSRTM4dHNfUDRETEpZcGU5?oc=5","date":"2025-10-04","type":"pipeline","source":"meyka.com","summary":"Japanese Pharma Stocks Surge Amid Influenza Outbreak - meyka.com","headline":"Japanese Pharma Stocks Surge Amid Influenza Outbreak","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE1YZDgwaWx4N2tNU19kck1Sejc0UFFQV3gzWXRjV2xncTBCQ3lnTndlbXh0UnFveTZBVFJROGdjZExJM2JySkRpeE1EZ0ZvSFVwYjFqamhDLUtIUjRHZnVhRG9nNlV2U2tKWTRVOE93Y20yd094S255UEFn?oc=5","date":"2025-09-26","type":"pipeline","source":"The Japan News","summary":"Japan’s Topix Posts Record-High Close despite US Tariffs on Pharma (UPDATE 1) - The Japan News","headline":"Japan’s Topix Posts Record-High Close despite US Tariffs on Pharma (UPDATE 1)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQdzVkTDgtZnBTZE9GNFpDS2FGWnZCWXFPWnJYTEpjQTh6VlFUaDlJQlc5NVc2YzZjZnRRWEhicUgxN1dVQldDUUR5Zk9YX0xaUURXR1FqNG5MTG9HV2VjYTZ0SEI2M24tXzhlY0dPMDZDNU5zYTFTZXF2cDdzaG80SXFOM2Rnd1RIWkw0VzJRb2xWLVB1eXZIck5HQnIxNzZ0Si1zalBNQ0NfNzNWU3loRk16WS02UQ?oc=5","date":"2022-03-17","type":"pipeline","source":"Reuters","summary":"AstraZeneca pays $775 mln to settle drug dispute with Japan's Chugai - Reuters","headline":"AstraZeneca pays $775 mln to settle drug dispute with Japan's Chugai","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE5qbl9Fc1cxYWk1QTlkV2JzZ08ybjZISE1JQnhEQUcydm80ZHRuc1dQRklkcTdiSXp3b0JzaGl0RnJxQ1RUeXpUakRrNm1zR0t1S19hVA?oc=5","date":"2018-07-05","type":"pipeline","source":"Yahoo Finance UK","summary":"Astellas Pharma Inc. (4503.T) stock price, news, quote and history - Yahoo Finance UK","headline":"Astellas Pharma Inc. (4503.T) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE1jU3RxdUhkaVZSWkFTUXZpX2xYZDVMVS1FXzhleExtYTZ1MGFYZktDVzk5TkpZTjAzV2RoUG9UTDhEZHdSeUJqVV90cDVpclY0SS1jMFNBeHk?oc=5","date":"2017-08-09","type":"pipeline","source":"TradingView","summary":"4519 Stock Price and Chart — TSE:4519 - TradingView","headline":"4519 Stock Price and Chart — TSE:4519","sentiment":"neutral"}],"patents":[{"drugName":"Roactemra","drugSlug":"tocilizumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1400000000},{"drugName":"Enspryng","drugSlug":"satralizumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":500000000}],"drugCount":4,"phaseCounts":{"marketed":1,"phase_1":1,"discontinued":1,"phase_3":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Takeda Pharmaceutical","Eisai Co., Ltd.","Ono Pharmaceutical Co., Ltd."],"therapeuticFocus":["Oncology","Rare Diseases","Antibody Engineering"],"financials":{"source":"yahoo_finance","revenue":7953295995.3874,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":7953295995.3874},{"period":"2024-12-31","value":7401154568.0254},{"period":"2023-12-31","value":7026586072.4038},{"period":"2022-12-31","value":7964581606.8364}],"grossProfit":5653876371.9214,"grossProfitHistory":[{"period":"2025-12-31","value":5653876371.9214},{"period":"2024-12-31","value":5255244550.1514},{"period":"2023-12-31","value":4413470707.9553995},{"period":"2022-12-31","value":4953498280.115}],"rdSpend":1186082989.6972,"rdSpendHistory":[{"period":"2025-12-31","value":1186082989.6972},{"period":"2024-12-31","value":1147149210.816},{"period":"2023-12-31","value":1105597928.7752},{"period":"2022-12-31","value":946006105.6963999}],"sgaSpend":736321341.7154,"operatingIncome":3786104515.8761997,"operatingIncomeHistory":[{"period":"2025-12-31","value":3786104515.8761997},{"period":"2024-12-31","value":3426792143.7427998},{"period":"2023-12-31","value":2776665054.6236},{"period":"2022-12-31","value":3371824577.3912}],"netIncome":2744028457.2567997,"netIncomeHistory":[{"period":"2025-12-31","value":2744028457.2567997},{"period":"2024-12-31","value":2448800655.2338},{"period":"2023-12-31","value":2057787411.5008},{"period":"2022-12-31","value":2367316643.8306}],"eps":263.72,"epsHistory":[{"period":"2025-12-31","value":263.72},{"period":"2024-12-31","value":235.36},{"period":"2023-12-31","value":197.8},{"period":"2022-12-31","value":227.57}],"cash":2697178944.1828,"cashHistory":[{"period":"2025-12-31","value":2697178944.1828},{"period":"2024-12-31","value":3415411695.2228},{"period":"2023-12-31","value":2899953246.9235997},{"period":"2022-12-31","value":1404657148.4666}],"totalAssets":15607621285.682999,"totalLiabilities":2799988651.6182,"totalDebt":null,"equity":12807632634.0648,"operatingCashflow":2442244252.3919997,"operatingCashflowHistory":[{"period":"2025-12-31","value":2442244252.3919997},{"period":"2024-12-31","value":2829938198.64},{"period":"2023-12-31","value":2591739088.645},{"period":"2022-12-31","value":1540040228.5548}],"capex":-705632065.5397999,"capexHistory":[{"period":"2025-12-31","value":-705632065.5397999},{"period":"2024-12-31","value":-347097357.3886},{"period":"2023-12-31","value":-469494081.2212},{"period":"2022-12-31","value":-450406540.0646}],"freeCashflow":1736612186.8522,"dividendsPaid":-1893068064.1166,"buybacks":-37934.8284,"employees":5104,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":null,"ebitda":null,"period":"2026-03-31","revenue":null,"epsBasic":70.13,"netIncome":null,"rdExpense":null,"epsDiluted":70.13,"grossProfit":null,"operatingIncome":null},{"sga":null,"ebit":null,"ebitda":null,"period":"2025-03-31","revenue":null,"epsBasic":59.09,"netIncome":null,"rdExpense":null,"epsDiluted":59.08,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":8096,"previousClose":7805,"fiftyTwoWeekHigh":10700,"fiftyTwoWeekLow":5942,"fiftyTwoWeekRange":"5942.0 - 10700.0","fiftyDayAverage":8658.9,"twoHundredDayAverage":7974.07,"beta":0.56,"enterpriseValue":78866525329.04207,"forwardPE":34.3,"priceToBook":6.98,"priceToSales":10.32,"enterpriseToRevenue":9.66,"enterpriseToEbitda":19.52,"pegRatio":2.39,"ebitda":4039275187.9712667,"ebitdaMargin":49.5,"freeCashflow":1948709663.37806,"operatingCashflow":2792275287.089971,"totalDebt":0,"debtToEquity":0,"currentRatio":4.7,"returnOnAssets":17.4,"returnOnEquity":23.7,"analystRating":"2.1 - Buy","recommendationKey":"buy","numberOfAnalysts":15,"targetMeanPrice":10096.67,"targetHighPrice":13500,"targetLowPrice":8200,"dividendRate":132,"payoutRatio":0.46,"fiveYearAvgDividendYield":1.67,"exDividendDate":1782691200,"insiderHeldPercent":59.9,"institutionHeldPercent":18.8,"sharesOutstanding":1645763056,"floatShares":639889134,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":263.81,"epsForward":235.91,"revenuePerShare":784.6,"bookValue":1159.17,"officers":[{"age":62,"name":"Dr. Osamu  Okuda","title":"President, CEO & Chairman"},{"age":59,"name":"Mr. Iwaaki  Taniguchi","title":"Senior Executive Officer, CFO, Head of Finance & Director"},{"age":null,"name":"Toshiya  Sasai","title":"Executive of Investor Relations Group & Corporate Communications Department"},{"age":null,"name":"Junichi  Takano","title":"Head of Marketing & Sales Division"},{"age":null,"name":"Mr. Shinji  Hidaka","title":"Executive Vice President"},{"age":null,"name":"Mr. Tetsuya  Yamaguchi","title":"Executive Vice President"},{"age":null,"name":"Mr. Yoshiyuki  Yano","title":"Executive Vice President"},{"age":null,"name":"Mr. Kosuke  Iijima","title":"Head of PHC Solution Department"}],"industry":"Drug Manufacturers - General","irWebsite":"http://www.chugai-pharm.co.jp/hc/ss/english/ir/index.html","website":"https://www.chugai-pharm.co.jp","phone":"81 3 3281 6611"}}